Stockreport

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Protara Therapeutics, Inc.  (TARA) 
PDF Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-00 [Read more]